Hypothesis

Chondroitin sulfate 6-O-sulfation (CS-6S) creates ECM microdomains that are preferentially cleaved by neutrophil elastase, releasing elastin-derived peptides that activate monocyte NEU1 and drive inflammaging.

Mechanistic rationale

• CS chains modulate protease accessibility; sulfation at the 6-O position increases electrostatic attraction for cationic elastase, accelerating local ECM breakdown.
• Elastin fragments generated in CS-6S-rich zones act as DAMPs, binding NEU1 on macrophages and triggering IL-1beta/TNF-alpha release (see [1]).
• Senescent cells upregulate chondroitin synthase and sulfotransferases (e.g., CHST11) as part of SASP, thereby increasing CS-6S deposition in surrounding matrix.
• Elevated CS-6S thus establishes a feed-forward loop: more sulfation -> more elastase cleavage -> more DAMPs -> more inflammation -> more senescence -> more sulfation.

Testable predictions

1. Biomarker shift - LC-MS/MS quantification of disaccharide isoforms will show a significant rise in the ΔDi-6S species (unsaturated chondroitin sulfate bearing 6-O-sulfonate) in skin, aorta, and cartilage of 24-month-old mice versus 3-month controls.
2. Causal link - Genetic knockdown of CHST11 in fibroblasts will reduce CS-6S levels, decrease elastase-mediated elastin fragment release in vitro, and lower NEU1-dependent cytokine production in co-cultured macrophages.
3. In vivo rescue - Administration of a selective CHST11 inhibitor (e.g., small-molecule sulfotransferase blocker) to aged mice will decrease CS-6S staining, lower circulating elastin peptides, and extend median lifespan by >=10% compared with vehicle.
4. Spatial correlation - Immunofluorescence of tissue sections will reveal colocalization of CS-6S signals with elastase activity (Elastase-specific substrate) and NEU1-positive macrophages, particularly in areas of SASP-rich senescent clusters.
5. Opposite manipulation - Overexpression of CHST11 in young mice will prematurely increase CS-6S, elevate elastin fragments, and accelerate age-related functional decline (grip strength, treadmill endurance).

Potential confounders & controls

• Changes in overall GAG content must be distinguished from specific sulfation shifts; therefore, total GAG assays (DMMB) will accompany sulfation measurements.
• Off-target effects of sulfotransferase inhibitors will be monitored via global sulfonylome profiling.
• Compensatory upregulation of other sulfation positions (4-O, N-acetyl) will be quantified to ensure specificity.

Implications

If validated, CS-6S would represent a concrete biochemical 'switch' that translates ECM remodeling into immune-driven aging, offering a druggable node upstream of the inflammaging loop highlighted by NEU1 inhibition [1]. Targeting the sulfation machinery could slow aging by breaking the matrix-immune feedback at its source, preceding downstream collagen loss or cytokine storms.